150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)

PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as monotherapy and with chemotherapy in 1L non-small cell lung cancer (NSCLC). This study will evaluate PF-08634404 in combination with different anticancer agents in advanced solid tumors including NSCLC.